MaaT Pharma Past Earnings Performance
Past criteria checks 0/6
MaaT Pharma's earnings have been declining at an average annual rate of -29.3%, while the Biotechs industry saw earnings growing at 17.7% annually. Revenues have been growing at an average rate of 45% per year.
Key information
-29.3%
Earnings growth rate
31.3%
EPS growth rate
| Biotechs Industry Growth | 30.8% |
| Revenue growth rate | 45.0% |
| Return on equity | -96.3% |
| Net Margin | -885.0% |
| Next Earnings Update | 14 May 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How MaaT Pharma makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 2 | -20 | 5 | 20 |
| 30 Sep 23 | 2 | -17 | 5 | 18 |
| 30 Jun 23 | 2 | -15 | 5 | 16 |
| 31 Mar 23 | 2 | -14 | 5 | 15 |
| 31 Dec 22 | 1 | -14 | 4 | 14 |
| 30 Sep 22 | 1 | -13 | 4 | 13 |
| 30 Jun 22 | 1 | -12 | 4 | 12 |
| 31 Mar 22 | 1 | -11 | 3 | 10 |
| 31 Dec 21 | 1 | -9 | 3 | 9 |
| 30 Sep 21 | 0 | -8 | 2 | 8 |
| 30 Jun 21 | -1 | -7 | 2 | 8 |
| 31 Mar 21 | 0 | -6 | 2 | 7 |
| 31 Dec 20 | 0 | -5 | 1 | 6 |
| 31 Dec 19 | 0 | -5 | 1 | 0 |
| 31 Dec 18 | 1 | -4 | 1 | 5 |
| 31 Dec 17 | 0 | -4 | 1 | 0 |
Quality Earnings: MAAT is currently unprofitable.
Growing Profit Margin: MAAT is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: MAAT is unprofitable, and losses have increased over the past 5 years at a rate of 29.3% per year.
Accelerating Growth: Unable to compare MAAT's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: MAAT is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-8.7%).
Return on Equity
High ROE: MAAT has a negative Return on Equity (-96.34%), as it is currently unprofitable.